AKROS STUDY

Patient Group:

Hepatitis C Non Responders

----------------------------------------------------------

Inclusions:

1. Genotype 1
   
   
2. Has completed at least twelve weeks of treatment with Pegylated Interferon and Ribavirin
   
   
3. Documented detectable levels of HCV-RNA during treatment
   
   
4. Compensated liver disease

-----------------------------------------------------------

Exclusions:

1. Any cause of liver disease other than chronic hepatitis C.
   
   
2. Relapser
   
   
3. Substance abuse less than two years
   
   
4. Coinfections: HIV or hepatitis B

-------------------------------------------------------------

This study will compare the safety and efficacy of JTK-003, a viral polymerase inhibitor, in combination with Pegylated Interferon to Ribavirin and Pegylated Interferon in a 12 week study. Sustained viral responses are possible but not expected with this short duration of treatment.

Please contact Nahid Attar at Nahid.Attar@UTSouthwestern.edu or at (214) 648-3690 or Rivka Elbein at Rivka.Elbein@UTSouthwestern.edu or at (214) 648-4801 for further information.

Study Sponsored by:  Akros Pharma Inc